Douglas Keith
General Practice · Goldsboro, NCNPI 1063444198
Payments from drug & device makers
Across 55 payments — averaging $20.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$194
- Baxter Healthcare$162
- Novartis$82
- AbbVie$79
- Preventric Diagnostics, Inc.$75
- Sanofi-aventis U.S. LLC$70
- plus $455 from 16 others
What the payments were for
- Food & beverage$95686%
- Other$16214%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 12 | $194 |
| Baxter Healthcare | 1 | $162 |
| Novartis | 5 | $82 |
| AbbVie | 5 | $79 |
| Preventric Diagnostics, Inc. | 1 | $75 |
| Sanofi-aventis U.S. LLC | 4 | $70 |
| Lilly USA, LLC | 5 | $69 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $66 |
| Johnson & Johnson | 3 | $48 |
| Exact Sciences | 2 | $39 |
| Amarin Pharma, Inc. | 2 | $33 |
| BD | 1 | $27 |
| GSK | 2 | $27 |
| Nestle Healthcare Nutrition Inc. | 1 | $20 |
| Boehringer Ingelheim | 1 | $19 |
| Bayer | 1 | $18 |
| Merck | 1 | $17 |
| Neurocrine Biosciences, Inc. | 1 | $16 |
| Arbor Pharmaceuticals, Inc. | 1 | $15 |
| Mylan Specialty L.p. | 1 | $15 |
| Medtronic | 1 | $15 |
| Ultragenyx Pharmaceutical Inc. | 1 | $13 |
How this compares
$1,118 in reported general payments places this provider in the 80th percentile of 2,924 general practice providers in North Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 30 | $32,982 |
| JardianceEmpagliflozin | 22 | $22,706 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 31 | $22,241 |
| FarxigaDapagliflozin Propanediol | 20 | $21,197 |
| JanuviaSitagliptin Phosphate | 18 | $17,708 |
| OzempicSemaglutide | 11 | $15,105 |
| TrulicityDulaglutide | 14 | $14,598 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 48 | $1,537 |
| Gabapentin | 85 | $1,462 |
| Ventolin HfaAlbuterol Sulfate | 17 | $869 |
| Levothyroxine Sodium | 77 | $790 |
| Atorvastatin Calcium | 113 | $714 |
| Omeprazole | 44 | $713 |
| Montelukast Sodium | 27 | $615 |
| Losartan Potassium | 52 | $558 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $19 | $22,70622 claims |
| GSKTrelegy Ellipta | $27 | $22,24131 claims |
| MerckJanuvia | $17 | $17,70818 claims |
| Novo NordiskOzempic | $194 | $15,10511 claims |
| Lilly USA, LLCTrulicity | $69 | $14,59814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,924 general practice providers in North Carolina.
Other general practice in Goldsboro
- Matthew MillerCharlotte$937K
- James BarberDurham$768K
- Robert LoweCharlotte$615K
- Howard JamesSanford$483K
- Clifton CameronFayetteville$404K
- Michael HarrisonRaleigh$249K
- Ronnie DavidsonMooresville$151K
- Leo HaydtHolly Springs$119K
- Andrew KellyGreensboro$115K
- Mark HymanGreensboro$95K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.